单细胞测序服务提供商Single Cell Discoveries收购TATAA Biocenter，打造端到端精准生物学CRO-动脉网

Single Cell Discoveries Acquires TATAA Biocenter to Create an End-to-End Precision Biology CRO

D-Pharm 等信源发布 2026-09-15 13:02



可切换为仅中文







Single Cell Discoveries (SCD), a specialist contract research organization (CRO) focused on discovery transcriptomics, has completed the acquisition of TATAA Biocenter, a globally recognized leader in qPCR, bioanalytical services, and molecular assay development. The combination creates one of Europe’s few specialist CROs able to take a molecular target from discovery to a validated, regulatory-ready result.

专注于发现转录组学的专业合同研究组织（CRO）Single Cell Discoveries（SCD）已完成对TATAA Biocenter的收购。TATAA Biocenter是全球公认的qPCR、生物分析服务和分子检测方法开发领域的领导者。此次合并使新实体成为欧洲少数几家能够将分子靶点从发现阶段推进至经过验证且符合监管要求结果的专业CRO之一。

Financial terms were not disclosed..

财务条款未予披露。

Together, the two organizations employ approximately 50 scientists across Utrecht and Gothenburg, supporting pharmaceutical, biotechnology, and academic customers from discovery through validation and clinical development.

这两家机构在乌得勒支和哥德堡共雇佣了约50名科学家，为制药、生物技术和学术领域的客户提供从发现到验证及临床开发的全程支持。

SCD contributes single-cell sequencing, spatial transcriptomics, high- throughput RNA sequencing, bioinformatics, and multi-omics. TATAA adds qPCR, dPCR, proteomics, RNA and DNA sequencing, and GLP/GCLP-compliant bioanalysis. A target identified by single-cell sequencing can now be confirmed with spatial transcriptomics or proteomics, then developed into a qPCR or RNA-seq assay validated under GCLP or GLP in Gothenburg, without the samples or the data leaving the group.

SCD 提供单细胞测序、空间转录组学、高通量 RNA 测序、生物信息学和多组学服务。TATAA 则提供 qPCR、dPCR、蛋白质组学、RNA 和 DNA 测序，以及符合 GLP/GCLP 规范的生物分析服务。通过单细胞测序鉴定的靶点，现在可以利用空间转录组学或蛋白质组学进行确认，然后在哥德堡开发成经过 GCLP 或 GLP 验证的 qPCR 或 RNA-seq 检测方法，整个过程无需将样本或数据移出集团内部。

SCD now pairs research-grade innovation with validated workflows suitable for preclinical and clinical use..

SCD 现在将研究级创新与经过验证的、适用于临床前和临床使用的工作流程相结合。

eMolecules acquires Synple Chem AG

eMolecules 收购 Synple Chem AG

'We are thrilled to welcome the highly reputable and talented Synple team into eMolecules'

“我们非常高兴欢迎享有盛誉且才华横溢的Synple团队加入eMolecules”

Read news

阅读新闻

“This is a natural fit,” said Mauro Muraro, CEO of Single Cell Discoveries. “Customers kept telling us the same thing: they loved working with us on discovery but had to go elsewhere to validate targets for a clinical program. TATAA closes that gap. As drug developers consolidate their outsourcing, working with fewer partners across more of the development pathway, this is the right move: the discovery-to-validation handover is one of the points where fragmentation costs sponsors the most time.”.

“这是水到渠成的合作，”Single Cell Discoveries 首席执行官毛罗·穆拉罗表示。“客户反复向我们反馈同样的问题：他们很享受与我们在发现阶段的合作，但为了验证临床项目的靶点，却不得不转向其他供应商。TATAA 填补了这一空白。随着药物研发企业整合其外包策略，在更广泛的开发路径上与更少的合作伙伴携手，此举可谓正当其时：从发现到验证的交接环节，正是碎片化导致申办方耗时最多的痛点之一。”

“Scientifically, this offers discovery coupled with rigor,” said Sofia Adolfsson, Scientific Officer of TATAA Biocenter. “SCD’s single-cell and spatial technologies generate exceptional insight, and our GLP/GCLP-compliant qPCR and assay development can now validate those findings — without customers switching providers, protocols, or data formats partway through a program.”.

“从科学角度来看，这提供了严谨性与发现机会的结合，”TATAA生物中心科学官索菲亚·阿道夫森表示。“SCD的单细胞和空间技术能够产生卓越的洞见，而我们符合GLP/GCLP规范的qPCR及检测方法开发现在可以验证这些发现——客户无需在项目中途更换供应商、实验方案或数据格式。”

For existing customers, projects, teams, workflows, and quality systems continue unchanged, and current contacts remain the point of entry. TATAA will continue to operate from Gothenburg with the same scientists. What is new is the option to extend a program across both organizations: combined services are available from September 2026..

对于现有客户，项目、团队、工作流程和质量体系均保持不变，当前联系人仍为对接入口。TATAA 将继续在哥德堡运营，并由相同的科学家团队提供服务。新增的选项是可将项目扩展至两家机构：自2026年9月起，可提供联合服务。

“Pairing regulated molecular analysis with SCD enables us to better serve clients as they advance towards the clinic, translating the powerful discoveries from single cell and spatial omics into validated biomarker assays,” says Peter Batesko, Lead Director of SCD and Managing Partner of Care Equity, an investment firm specialized in outsourced drug development services which provided growth capital to SCD in 2022.

“将配对调控分子分析与SCD相结合，使我们能够在客户向临床应用推进的过程中更好地为其提供服务，将来自单细胞和空间组学的强大发现转化为经过验证的生物标志物检测方法。”SCD首席总监兼Care Equity管理合伙人Peter Batesko表示。Care Equity是一家专注于外包药物开发服务的投资公司，曾于2022年为SCD提供增长资本。

“We are excited to see the teams combine their strengths and continue to build lasting, impactful client partnerships.”.

“我们很高兴看到各团队发挥各自优势，持续建立持久且富有影响力的客户关系。”

Judith Vivie, COO and Mauro Muraro, CEO will lead the combined organization. The Gothenburg site will continue to be managed locally, with its scientific and customer-facing teams in place. Together, the two teams will continue to serve academic, biotech and pharma customers across the life sciences..

首席运营官朱迪思·维维（Judith Vivie）和首席执行官毛罗·穆拉罗（Mauro Muraro）将领导合并后的组织。哥德堡站点将继续由本地团队管理，其科研及客户面向团队保持不变。两支团队将携手继续为生命科学领域的学术机构、生物科技公司和制药公司客户提供服务。

https://www.bionity.com/en/news/1189822/single-cell-discoveries-acquires-tataa-biocenter-to-create-an-end-to-end-precision-biology-cro.html

Protagen Protein Services and BioAnalytix Merge

Protagen 蛋白质服务公司与 BioAnalytix 合并

Create Global Analytic Service Partner for Biopharmaceuticals

创建生物制药全球分析服务合作伙伴

Read news

阅读新闻